Gvoke Vialdx Injection, Solution
Product Images NDC 0517-2901

Product Visual Gallery

This gallery contains 54 technical images submitted to the FDA as part of the official labeling for Gvoke Vialdx (NDC 0517-2901). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Regent, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Its Molecular Formula Is C153h225n43o49s With The Following Structure: (Gvoke Vialdx Glucagon Injection 1)

Chemical structure diagram showing the amino acid sequence of glucagon, a 29-residue peptide consisting of specific amino acids labeled by position number and one-letter codes.*

FDA Label Image

Ifua-sideb-f2 (Gvoke Vialdx Glucagon Injection 10)

An instructional illustration showing a hand holding a syringe or vial with a magnified view of an eye looking at the expiration date (EXP: YYYY MM) printed on the side of the container. The image emphasizes checking the expiration date before use.*

FDA Label Image

Ifua-sideb-f3 (Gvoke Vialdx Glucagon Injection 11)

An instructional illustration showing a hand holding a Gvoke VialDx injection vial with an integrated window. A close-up depiction highlights the vial's inspection window, emphasizing visual confirmation of liquid level or clarity before use.*

FDA Label Image

Ifua-sideb-f4 (Gvoke Vialdx Glucagon Injection 12)

An instructional illustration showing a hand pulling off the red cap from a vial or similar container. A black arrow indicates the motion of removing the cap. The text below the image reads 'Pull Off Red Cap.' This image likely demonstrates a step in preparing the Gvoke VialDx glucagon injection for intravenous use.*

FDA Label Image

Ifua-sideb-f5 (Gvoke Vialdx Glucagon Injection 13)

An illustration showing the recommended injection sites for Gvoke VialDx glucagon injection solution. The front view highlights the abdomen around the navel and front thigh areas, while the back view highlights the upper outer arm sites for intravenous injection.*

FDA Label Image

Ifua-sideb-f6 (Gvoke Vialdx Glucagon Injection 14)

Illustration showing how to expose the skin at the injection site. It depicts a person lifting their shirt and rolling up their shorts to show the upper arm and thigh areas as possible injection sites for glucagon injection.*

FDA Label Image

Ifua-sideb-f7 (Gvoke Vialdx Glucagon Injection 15)

An instructional illustration showing how to use an injection device: a hand pressing down on the device to inject, accompanied by the word "Click," followed by a stopwatch indicating to hold down the device for 5 seconds.*

FDA Label Image

Ifua-sideb-f8 (Gvoke Vialdx Glucagon Injection 16)

An instructional illustration showing the proper alignment for visualizing a red indicator window on a Gvoke VialDx glucagon injection vial. The diagram highlights the eye level check needed to confirm the indicator is fully visible, representing readiness or correct assembly of the injection vial.*

FDA Label Image

Ifua-sideb-f9 (Gvoke Vialdx Glucagon Injection 17)

An instructional diagram showing a hand lifting a Gvoke VialDx glucagon injection device away from the skin after use, with a yellow needle guard locking over the needle to promote safety and prevent needle exposure.*

FDA Label Image

Ifua-sideb-f10 (Gvoke Vialdx Glucagon Injection 18)

Illustration showing a person rolling onto their side, depicted in two frames with an arrow indicating the rolling motion. The first frame shows the person lying on their back, and the second frame shows them on their side with one arm extended.*

FDA Label Image

Ifua-sideb-f11 (Gvoke Vialdx Glucagon Injection 19)

Instructional diagram showing proper disposal of a used Gvoke VialDx glucagon injection device. The top panel illustrates removing the red cap from the device by pulling it off horizontally. The bottom panel depicts a hand placing the used injection device into a red sharps disposal container labeled "SHARPS CONTAINER."*

FDA Label Image

Figure 1 (Gvoke Vialdx Glucagon Injection 2)

A line graph showing mean plasma glucose levels (mg/dL) over time (minutes) following administration of 1 mg Gvoke glucagon injection (N=154). The graph displays an upward trend in glucose levels from baseline to 90 minutes, with error bars indicating variability.*

FDA Label Image

Pfs Pouch 1 mg (Gvoke Vialdx Glucagon Injection 20)

This label for Gvoke PFS glucagon injection 1 mg per 0.2 mL contains step-by-step illustrated instructions for preparing, injecting, and assisting after administration. It shows injection sites on the body, needle removal, syringe parts, needle angle, and patient positioning during use. It includes cautions such as not removing air bubbles or recapping the syringe, and disposal guidance for used syringes.*

FDA Label Image

Pfs Image (Gvoke Vialdx Glucagon Injection 21)

An instructional diagram of the Gvoke VialDx glucagon injection syringe components. The illustration labels the needle cap, needle, viewing window/syringe body, finger flange, and plunger, showing the parts of the intravenous injection device.*

FDA Label Image

Ifub Slideb-f1 (Gvoke Vialdx Glucagon Injection 22)

Instructional illustration showing the process of removing a backing from an adhesive label and attaching it to a medication vial, followed by drawing medication from the vial into a syringe. The steps suggest proper preparation of Gvoke VialDx glucagon injection (1 mg/0.2 mL) for intravenous administration.*

FDA Label Image

Ifub Slideb-f2 (Gvoke Vialdx Glucagon Injection 23)

An instructional illustration demonstrating the correct method to check the expiration date on a Gvoke VialDx glucagon injection vial. The image highlights the vial label where the expiration date (EXP: YYYY MM) is located, with a hand holding the vial and an eye indicating the need to visually verify the date before use.*

FDA Label Image

Ifub Slideb-f3 (Gvoke Vialdx Glucagon Injection 24)

An instructional illustration showing a hand holding an injection device for Gvoke VialDx glucagon injection. The diagram highlights the viewer's attention directed to the device tip, emphasizing proper visual inspection before use.*

FDA Label Image

Ifub Slideb-f4 (Gvoke Vialdx Glucagon Injection 25)

Illustration showing the front and back views of a human body with highlighted blue areas indicating recommended injection sites for a medication. The front view highlights areas on the abdomen and thighs, while the back view highlights the upper arms.*

FDA Label Image

Ifub Slideb-f5 (Gvoke Vialdx Glucagon Injection 26)

An instructional illustration showing a person exposing the skin at the injection site for an intravenous injection. The person is lifting their shirt to reveal the abdomen and pulling up their shorts to expose the thigh, indicated by arrows pointing to these areas.*

FDA Label Image

Ifub Slideb-f6 (Gvoke Vialdx Glucagon Injection 27)

Illustration showing how to remove the needle cap from a syringe. The image depicts a hand pulling the needle cap upward off the needle, with an arrow indicating the direction to pull. The text 'Pull Off Needle Cap' is displayed at the top left.*

FDA Label Image

Ifub Slideb-f7 (Gvoke Vialdx Glucagon Injection 28)

Illustration showing a hand pinching a fold of skin. The top of the image has a yellow label with the word 'Pinch'. This instructional graphic depicts a technique related to medication administration or skin preparation.*

FDA Label Image

Ifub Slideb-f8 (Gvoke Vialdx Glucagon Injection 29)

An instructional illustration showing the proper technique to insert a syringe needle at a 90-degree angle into the skin, depicting a hand holding the syringe and another hand stabilizing the insertion site.*

FDA Label Image

Figure 2 (Gvoke Vialdx Glucagon Injection 3)

A line graph depicting mean plasma glucose levels (mg/dL) over time in minutes for three pediatric age groups after glucagon injection: ages 2 to under 6 years (0.5 mg), ages 6 to under 12 years (0.5 mg), and ages 12 to under 18 years (1 mg). The graph shows glucose levels rising from baseline to approximately 200 mg/dL over 90 minutes with error bars indicating variability.*

FDA Label Image

Ifub Slideb-f9 (Gvoke Vialdx Glucagon Injection 30)

An instructional illustration showing a hand pushing down on the plunger of a syringe as the needle is inserted into a patient's arm. The image is labeled with the instruction 'Push' and depicts the action of administering an injection.*

FDA Label Image

Ifub Slideb-f10 (Gvoke Vialdx Glucagon Injection 31)

An instructional illustration showing a hand drawing fluid with a syringe from a vial, with another hand pulling the syringe upward, indicating the process of withdrawing medication for injection.*

FDA Label Image

Ifub Slideb-f11 (Gvoke Vialdx Glucagon Injection 32)

Two-panel instructional illustration showing a person rolling from lying face-up to lying on their side. The first panel shows the individual on their back with an arrow indicating the rolling motion. The second panel shows the person lying on their side with one arm extended forward.*

FDA Label Image

Ifub Slideb-f12 (Gvoke Vialdx Glucagon Injection 33)

An instructional illustration showing a hand holding a syringe above a red sharps container labeled with a biohazard symbol and the text 'SHARPS CONTAINER,' indicating proper disposal of the syringe into the container.*

FDA Label Image

Full Vial And Syringe (Gvoke Vialdx Glucagon Injection 34)

An instructional illustration showing the components of the Gvoke VialDx glucagon injection package, including a vial with a blue cap, a syringe body with plunger and needle, and a red needle cap. A note indicates that each vial and syringe should be used only once and then discarded.*

FDA Label Image

Gvoke Kit Figure A (Gvoke Vialdx Glucagon Injection 35)

An instructional illustration showing the contents of a Gvoke VialDx package, which includes a vial of glucagon injection (1 mg/0.2 mL) and a prefilled syringe within the box. The image depicts the vial and syringe being taken out of the packaging, indicating the components provided for intravenous administration.*

FDA Label Image

Gvoke Kit Figure B (Gvoke Vialdx Glucagon Injection 36)

An illustration showing a vial of Gvoke VialDx injection solution with a blue cap and a label. A magnified view highlights the area on the vial label where the expiration date (EXP YYYY MM) can be found. The image indicates where to check for the expiration date on the vial.*

FDA Label Image

Gvoke Kit Figure C (Gvoke Vialdx Glucagon Injection 37)

An illustration showing a vial of injection solution with a liquid inside and a blue cap. The vial is connected by dotted lines to an icon of an eye, suggesting guidance related to eye exposure or safety.*

FDA Label Image

Gvoke Kit Figure D (Gvoke Vialdx Glucagon Injection 38)

An instructional illustration showing a hand removing a flip-off cap from the top of a vial. The vial is held upright, and an arrow indicates the direction to lift the cap upwards.*

FDA Label Image

Gvoke Kit Figure E (Gvoke Vialdx Glucagon Injection 39)

An instructional illustration showing a hand peeling a protective tab or seal from a rectangular packaging or medical product container, indicated by a bold arrow pointing to the action.*

FDA Label Image

Figure 3 (Gvoke Vialdx Glucagon Injection 4)

A line graph depicting the mean glucagon concentration (pg/mL) over time (minutes) after injection of 1 mg Gvoke. The graph shows glucagon levels rising rapidly to peak between 20 and 40 minutes, then gradually declining to near baseline by 240 minutes post-injection.*

FDA Label Image

Gvoke Kit Figure F (Gvoke Vialdx Glucagon Injection 40)

An instructional illustration showing a hand pulling a red tab from a cap, with an arrow indicating the direction to pull, and another hand holding a syringe, demonstrating preparation steps for an injection.*

FDA Label Image

Gvoke Kit Figure G (Gvoke Vialdx Glucagon Injection 41)

An instructional illustration showing a hand holding a syringe and pushing the plunger downward into a vial, which is held steady by another hand. The image demonstrates the technique for withdrawing injection solution from the vial, likely for glucagon injection (Gvoke VialDx) preparation.*

FDA Label Image

Gvoke Kit Figure H (Gvoke Vialdx Glucagon Injection 42)

An instructional illustration showing a hand holding a vial and a syringe. The image includes an arrow indicating the action of drawing fluid from the vial into the syringe, demonstrating proper technique for preparing an injection.*

FDA Label Image

Gvoke Kit Figure I (Gvoke Vialdx Glucagon Injection 43)

An instructional diagram of a Gvoke VialDx glucagon injection vial showing volume graduations. The image highlights 0.1 mL marked for pediatric dose and 0.2 mL marked for adult dose with black arrows, indicating the appropriate dosage volumes for each patient group.*

FDA Label Image

Gvoke Kit Figure J (Gvoke Vialdx Glucagon Injection 44)

An anatomical illustration showing front and back views of a human torso indicating recommended injection sites for Gvoke VialDx glucagon injection. The highlighted areas for injection are the lower abdomen, outer thigh, and outer upper arm, on both front and back views.*

FDA Label Image

Gvoke Kit Figure K (Gvoke Vialdx Glucagon Injection 45)

An instructional illustration showing a person partially lifting their shirt and shorts to expose the skin on the upper arm and thigh, indicating recommended injection sites for administration. The diagram includes directional arrows emphasizing these areas.*

FDA Label Image

Gvoke Kit Figure L (Gvoke Vialdx Glucagon Injection 46)

An instructional illustration showing a hand pinching the skin on the forearm, demonstrating a technique likely related to preparing for injection.*

FDA Label Image

Gvoke Kit Figure M (Gvoke Vialdx Glucagon Injection 47)

An instructional illustration demonstrating the proper technique for injecting Gvoke VialDx glucagon injection solution intravenously. It shows a hand holding a syringe inserted at a 90-degree angle into the skin of the opposite hand, indicating the correct angle for intravenous injection.*

FDA Label Image

Gvoke Kit Figure N (Gvoke Vialdx Glucagon Injection 48)

An instructional illustration showing a hand inserting a syringe needle at an angle into a person's skin, suggesting the intravenous route for injection administration.*

FDA Label Image

Gvoke Kit Figure O (Gvoke Vialdx Glucagon Injection 49)

An instructional illustration showing a hand withdrawing glucagon injection from a vial using a syringe. The syringe is being pulled upward to draw the solution, with the vial held steady below. This depicts preparation for intravenous administration of Gvoke VialDx glucagon injection.*

FDA Label Image

Figure 4 (Gvoke Vialdx Glucagon Injection 5)

A line graph showing mean glucagon concentration (pg/mL) over time (minutes) from injection for three groups (G1, G2, G3) differentiated by age and dose. G1 and G2 received 0.5 mg doses with ages 2-6 and 6-12 years respectively, while G3 received 1 mg with ages 12-18 years. Data points include error bars, with glucagon levels peaking around 30 to 40 minutes and declining afterwards.*

FDA Label Image

Gvoke Kit Figure P (Gvoke Vialdx Glucagon Injection 50)

An instructional diagram showing a person lying on their side with the head turned downwards, illustrating the recovery position often used for unconscious individuals to maintain an open airway safely during emergency medical situations.*

FDA Label Image

Gvoke Kit Figure Q (Gvoke Vialdx Glucagon Injection 51)

An illustration showing a hand disposing of a syringe into a red sharps container labeled 'SHARPS CONTAINER'. An arrow points downward indicating proper disposal method for needles or syringes.*

FDA Label Image

Vial Label (Gvoke Vialdx Glucagon Injection 52)

Label for Gvoke VialDx (glucagon injection) 1 mg per 0.2 mL injection solution for intravenous use. Distributed by American Regent, Inc., Shirley, NY. Includes NDC 0517-2901-01 and notes to discard unused portion after dilution. Label specifies diagnostic use only.*

FDA Label Image

Carton (Single Pack)

Packaging label for Gvoke VialDx (glucagon injection) 1 mg per 0.2 mL, an intravenous injection solution by American Regent, Inc. The carton includes storage instructions, usage as a diagnostic reagent requiring dilution with 0.9% Sodium Chloride Injection, and details on vial contents and distributor information.*

FDA Label Image

Carton (10 Pack)

Gvoke VialDx 1 mg/0.2 mL vial label for glucagon injection, a human prescription drug for intravenous use. The label indicates it is for diagnostic purposes only with ten single-dose vials per package. It includes storage instructions and is distributed by American Regent, Inc.*

FDA Label Image

Ai Pouch 1 mg (Gvoke Vialdx Glucagon Injection 6)

Gvoke HypoPen glucagon injection label shows 1 mg per 0.2 mL strength in an auto-injector designed for low blood sugar emergency treatment. The illustrated instructions detail preparation, injection sites (lower abdomen, outer thigh, outer upper arm), injection steps, and patient assistance. The label includes red cap and needle end visuals and emphasizes disposal instructions. American Regent, Inc. is the manufacturer.*

FDA Label Image

Ai Pouch 0.5 mg (Gvoke Vialdx Glucagon Injection 7)

Gvoke HypoPen glucagon injection 0.5 mg per 0.1 mL labeled as an emergency treatment for low blood sugar. The label includes step-by-step illustrated instructions on how to prepare, inject, and assist the patient. It shows the injection sites on the lower abdomen, outer thigh, or outer upper arm. The label also displays the auto-injector device with red cap and needle end. Rx only.*

FDA Label Image

Ai Image (Gvoke Vialdx Glucagon Injection 8)

An illustration diagram showing the components of a Gvoke VialDx glucagon injection device. Labeled parts include a red cap, needle end, yellow needle guard, and a medication viewing window on the injection solution container.*

FDA Label Image

Ifua-sideb-f1 (Gvoke Vialdx Glucagon Injection 9)

An instructional diagram showing two sequential steps to use an injection device. The first step illustrates removing a strip from the packaging, indicated by a hand peeling it away. The second step depicts a hand holding a device and another hand pointing to a section of the device, suggesting an activation or preparation movement before use.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.